(Q38293513)

English

ApoA-I mimetics

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

1 reference

Europe PubMed Central

ApoA-I mimetics (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

author name string

R M Stoekenbroek

1

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

E S Stroes

2

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

G K Hovingh

3

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

publication date

1 January 2015

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Handbook of experimental pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

224

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

631-648

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Antiinflammatory properties of HDL.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

A novel approach to oral apoA-I mimetic therapy

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Inhibition of Atherosclerosis Development in Cholesterol-Fed Human Apolipoprotein A-I–Transgenic Rabbits

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

A multiple ascending dose study of CSL112, an infused formulation of ApoA-I.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Trimerization of apolipoprotein A-I retards plasma clearance and preserves antiatherosclerotic properties

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Mutation in APOA1 predicts increased risk of ischaemic heart disease and total mortality without low HDL cholesterol levels

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type).

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Meta-analysis: Statin Therapy Does Not Alter the Association Between Low Levels of High-Density Lipoprotein Cholesterol and Increased Cardiovascular Risk

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Reconstituted HDL for the acute treatment of acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Endothelial and antithrombotic actions of HDL.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Intravenous Injection of Rabbit Apolipoprotein A-I Inhibits the Progression of Atherosclerosis in Cholesterol-Fed Rabbits

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Trimerized apolipoprotein A-I (TripA) forms lipoproteins, activates lecithin:cholesterol acyltransferase, elicits lipid efflux, and is transported through aortic endothelial cells

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Effect of treatment with human apolipoprotein A-I on atherosclerosis in uremic apolipoprotein-E deficient mice

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Heart disease and stroke statistics--2012 update: a report from the American Heart Association

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Nanobiotechnology applications of reconstituted high density lipoprotein

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Effects of Recombinant Apolipoprotein A-I Milano on Aortic Atherosclerosis in Apolipoprotein E–Deficient Mice

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Recombinant apolipoprotein A-IMilano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Biological nanoparticles and their influence on organisms

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Effect of end group blockage on the properties of a class A amphipathic helical peptide

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function.

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust mite-induced asthma

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-09665-0_21

31 March 2020

Identifiers

10.1007/978-3-319-09665-0_21

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

release_tvkjb4mu3rdbznnislccnlomvi

1 reference

https://api.fatcat.wiki/v0/release/tvkjb4mu3rdbznnislccnlomvi

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38293513&oldid=1844679915"